GlaxoSmithKline boosted its pipeline of drugs today with a $3bn (€2.44bn) deal for its American partner on a potential blockbuster medicine.

GlaxoSmithKline will take its $2.6bn (€2bn) bid for Human Genome Sciences direct to shareholders this week after its takeover offer was rejected last month by the US biotech group’s board.